Anti-interleukin 5 therapies in severe asthma
- 30 May 2017
- journal article
- editorial
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 5 (7), 537-538
- https://doi.org/10.1016/s2213-2600(17)30206-0
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Respiratory Medicine, 2017
- The current and future role of biomarkers in type 2 cytokine‐mediated asthma managementClinical and Experimental Allergy, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Characterization of asthma endotypes: implications for therapyAnnals of Allergy, Asthma & Immunology, 2016
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disordersCurrent Opinion in Allergy and Clinical Immunology, 2016
- Reductions in eosinophil biomarkers by benralizumab in patients with asthmaRespiratory Medicine, 2016
- Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?Expert Review of Respiratory Medicine, 2015
- Allergen ImmunotherapyImmunology and Allergy Clinics of North America, 2015
- Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsJournal of Allergy and Clinical Immunology, 2013